Oura Inc.
No SEC Form 4 filings for $OURA in the last 30 days.
See all $OURA insider activity →Oura, a health tracking ring maker, filed for an IPO aiming to raise $2.2B by selling 50M shares at $40-$44 each. Its revenue rose to $1.2B in nine months, with a net loss of $924M. Nvidia's CEO Jensen Huang dismissed AI doomsday fears in a CBS interview, stating concerns lack factual and scientific grounding.
Oura, a smart ring maker, aims for a $15.62 billion valuation in its US IPO, offering 50 million shares at $40-$44 each to raise up to $2.2 billion. Investors like Eli Lilly and Dragoneer have shown interest. Oura's revenue grew 74% YoY to $1.21 billion for the nine months ended June 30. The company will list on Nasdaq as 'OURA'.
Oura, a maker of smart rings, plans to raise up to $2.2 billion in a US IPO, selling 50 million shares at $40-$44 each. Eli Lilly and Dragoneer may invest $100M and $300M, respectively. The company will list on Nasdaq as 'OURA'.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning OURA (Oura Inc.). Coverage has skewed bullish: 7 bullish, 3 neutral, and 0 bearish.
Oura, a health tracking ring maker, filed for an IPO aiming to raise $2.2B by selling 50M shares at $40-$44 each. Its revenue rose to $1.2B in nine months, with a net loss of $924M. Nvidia's CEO Jensen Huang dismissed AI doomsday fears in a CBS interview, stating concerns lack factual and scientific grounding.
The IPO could add a high‑growth consumer‑tech stock to the market, attracting growth‑oriented capital.
The IPO filing introduces a sizable new public float and capital for Oura, likely driving initial volatility.
New capital raise of ~ $2 bn, likely to generate strong initial trading volume and price volatility.
Oura, a wearable ring maker, filed for an IPO with a potential valuation of over $11 billion, according to The Wall Street Journal. The company reported $60.8 million in net income for the nine months ending June 30, with revenue growth over the past three years. Oura is involved in a blood pressure study and plans to introduce FDA-regulated features, which could impact its future offerings and regulatory landscape.
AlphAI scores every news story that mentions OURA with an AI model for sentiment and relevance, and aggregates insider trades from Oura Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oura, a health tracking ring maker, filed for an IPO aiming to raise $2.2B by selling 50M shares at $40-$44 each. Its revenue rose to $1.2B in nine months, with a net loss of $924M. Nvidia's CEO Jensen Huang dismissed AI doomsday fears in a CBS interview, stating concerns lack factual and scientific grounding.
2 min readOura, a smart ring maker, aims for a $15.62 billion valuation in its US IPO, offering 50 million shares at $40-$44 each to raise up to $2.2 billion. Investors like Eli Lilly and Dragoneer have shown interest. Oura's revenue grew 74% YoY to $1.21 billion for the nine months ended June 30. The company will list on Nasdaq as 'OURA'.
2 min readOura, a maker of smart rings, plans to raise up to $2.2 billion in a US IPO, selling 50 million shares at $40-$44 each. Eli Lilly and Dragoneer may invest $100M and $300M, respectively. The company will list on Nasdaq as 'OURA'.
2 min readOura, a health-tracking smart ring maker, launched an IPO of 50 million shares, priced between $40 and $44 per share. The company will not receive proceeds from 36.5 million shares sold by existing stockholders. Oura aims to list on Nasdaq under the ticker OURA.
1 min readOura, a wearable ring maker, filed for an IPO with a potential valuation of over $11 billion, according to The Wall Street Journal. The company reported $60.8 million in net income for the nine months ending June 30, with revenue growth over the past three years. Oura is involved in a blood pressure study and plans to introduce FDA-regulated features, which could impact its future offerings and regulatory landscape.
2 min read
